Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Nplate (romiplostim by Year
Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide volume growth YoY (%) (%)
Amgen Nplate (romiplostim: 8.0% in FY2024. No newer figure appears in the documents we track.
Latest, FY2024
8.0%
Period ended Dec 31, 2024
Change on a year earlier
–
History
2 years
Since FY2021
Sources
2
Documents cited below
Where the FY2024 figure comes from
“government orders, Nplate sales grew 12% year-over-year for the full year, driven by 8% volume growth and 6% higher net selling price.”
Source: Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 8.0% | – | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2021 | Dec 31, 2021 | 17.0% | – | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
Cite this data
StockData. (2026). Amgen Nplate (romiplostim (%), annual FY2021–FY2024 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-nplate-vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.